Xeris Pharmaceuticals Statistics
Want to see XERS full AI Analyst Report?
Xeris Pharmaceuticals (XERS) Stock Statistics & Valuation Metrics
Total Valuation
Xeris Pharmaceuticals has a market cap or net worth of $3.04B. The enterprise value is $1.91B.
- Market Cap
- $3.04B
- Enterprise Value
- $1.91B
Share Statistics
Xeris Pharmaceuticals has 182,700,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 182,700,040
- Owned by Insiders
- 4.85%
- Owned by Institutions
- 38.13%
Financial Efficiency
Xeris Pharmaceuticals’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 8.89%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 8.89%
- Return on Capital Employed (ROCE)
- 0.09
- Revenue Per Employee
- 670.91K
- Profits Per Employee
- 1,273.563
- Employee Count
- 435
- Asset Turnover
- 0.76
- Inventory Turnover
- 0.78
Valuation Ratios
The current PE Ratio of Xeris Pharmaceuticals is -415.46. Xeris Pharmaceuticals’s PEG ratio is 0.04.
- PE Ratio
- -415.46
- PS Ratio
- 8.27
- PB Ratio
- 61.79
- Price to FCF
- 41.91
- Price to Operating Cash Flow
- 40.93
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, Xeris Pharmaceuticals had revenue of 291.85M and earned 554.00K in profits. Earnings per share was 0.00.
- Revenue
- 291.85M
- Gross Profit
- 238.43M
- Operating Income
- 24.90M
- Pretax Income
- 554.00K
- Net Income
- 554.00K
- EBITDA
- 12.71M
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was 73.65M and capital expenditures -1.03M, giving a free cash flow of 72.62M billion.
- Operating Cash Flow
- 73.65M
- Free Cash Flow
- 72.62M
- Free Cash Flow per Share
- 0.40
Dividends & Yields
Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.39%
- Earnings Yield
- -0.22%
Stock Price Statistics
- Beta
- 0.82
- 52-Week Price Change
- 129.48%
- 50-Day Moving Average
- 10.40
- 200-Day Moving Average
- 7.83
- Relative Strength Index (RSI)
- 85.41
- Average Volume (3m)
- 2.77M
Important Dates
Xeris Pharmaceuticals upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Xeris Pharmaceuticals as a current ratio of 2.19, with Debt / Equity ratio of 275.86%
- Current Ratio
- 2.19
- Quick Ratio
- 1.57
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- -5.77
- Interest Coverage Ratio
- 0.86
Taxes
In the past 12 months, Xeris Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Xeris Pharmaceuticals EV to EBITDA ratio is 119.41, with an EV/FCF ratio of 43.22.
- EV to Sales
- 8.52
- EV to EBITDA
- 119.41
- EV to Free Cash Flow
- 43.22
- EV to Operating Cash Flow
- 42.62
Balance Sheet
Xeris Pharmaceuticals has $131.08M in cash and marketable securities with $226.07M in debt, giving a net cash position of -$94.98M billion.
- Cash & Marketable Securities
- $131.08M
- Total Debt
- $226.07M
- Net Cash
- -$94.98M
- Net Cash Per Share
- -$0.52
- Tangible Book Value Per Share
- -$0.30
Margins
Gross margin is 84.44%, with operating margin of 12.70%, and net profit margin of -1.76%.
- Gross Margin
- 84.44%
- Operating Margin
- 12.70%
- Pretax Margin
- -1.76%
- Net Profit Margin
- -1.76%
- EBITDA Margin
- 7.14%
- EBIT Margin
- 3.74%
Analyst Forecast
The average price target for Xeris Pharmaceuticals is $17.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $17.17
- Price Target Upside
- 3.04% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 38.37%
- EPS Growth Forecast
- 63.43%
Scores
- Smart Score
- 8
- AI Score
- 64

